Press Releases April 7, 2026 08:00 PM

BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Nearly RMB721 Million in 2026

KANZHUN LIMITED Continues Aggressive Share Buyback Program in 2026, Reflecting Strong Commitment to Shareholder Value

By Sofia Navarro BZ
BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Nearly RMB721 Million in 2026
BZ

KANZHUN LIMITED, operating as BOSS Zhipin, announced ongoing share repurchases totaling nearly RMB721 million so far in 2026, including a recent purchase of approximately RMB27.3 million for 603,724 shares. The program highlights the company's dedication to enhancing shareholder returns.

Key Points

  • KANZHUN LIMITED has executed share repurchases worth nearly RMB721 million year-to-date in 2026.
  • On April 7, 2026, the company repurchased 603,724 ordinary shares for RMB27.3 million.
  • The buyback program signals management's confidence in the company's valuation and a commitment to returning value to shareholders.

BEIJING, April 08, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB27.3 million to repurchase 603,724 ordinary shares on April 7. Year-to-date in 2026, the Company has deployed nearly RMB721 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Continued large-scale share repurchases may strain company cash flow or limit funds for growth initiatives.
  • Market conditions or regulatory changes in China or the U.S. could impact the company's operational performance or stock price.
  • Uncertainty related to the company’s future earnings growth might affect market perception despite buybacks.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026